This Unpopular Dividend Stock Is a Buy
This double-digit growth in new drug sales showcases the company's ability to successfully commercialize cutting-edge ...
Weight-loss drugs like Ozempic may be up for Medicare price negotiations — will Trump support it?
Medicare’s drug pricing negotiations — the first of their kind in the United States, passed under President Joe Biden — face ...
Should Bristol-Myers Squibb Company (NYSE:BMY) Be In Your Early Retirement Portfolio?
We recently compiled a list of the Early Retirement Portfolio: 10 Stocks to Live Off Dividends. In this article, we are going ...
FDA approves injectable version of Bristol Myers Squibb's cancer drug Opdivo
The U.S. Food and Drug Administration said on Friday that it has approved an injectable version of Bristol Myers Squibb's ...
Study identifies risk potential for thousands of mutations of a cancer gene
Scientists have characterized the role of thousands of mutations in the BRCA2 cancer gene, findings that may help reassure ...
Bristol Myers Squibb Co. stock outperforms competitors despite losses on the day
The stock's fall snapped a two-day winning streak.
Bristol Myers Squibb Co. stock underperforms Tuesday when compared to competitors despite daily gains
This was the stock's second consecutive day of gains.
Hosted on MSN1d
High Response Rate in Heavily Treated Multiple Myeloma With Novel Drug Combination
A novel combination for relapsed/refractory multiple myeloma produced responses in about 80% of a heavily treated population, ...
Truist Financial Remains a Buy on Bristol-Myers Squibb (BMY)
In a report released yesterday, Srikripa Devarakonda from Truist Financial maintained a Buy rating on Bristol-Myers Squibb (BMY – Research ...
kalkinemedia1d
Bristol-Myers Squibb (NYSE:BMY) Reports Robust Quarterly Earnings
Highlights,Bristol-Myers Squibb beats quarterly earnings estimates.,Dividend increased, maintaining strong returns.,Insider ...
Obesity Treatments, M&A Activity To Take Center Stage During Upcoming JPM Healthcare Conference
JP Morgan highlights mixed sentiment for U.S. large-cap biopharma stocks as advancements in obesity drugs and key product launches shape 2025 outlook.